earn icn pharmaceut inc costa mesa base drug maker said earn fell 46 3 million second quarter sale 9 44 5 million icn said unfavor quarter quarter comparison net incom result debt repurchas gain compani invest portfolio last year second quarter well substanti higher research develop spend viratek inc year second quarter said pharmaceut biomed oper regist solid gain quarter